Nano-X Imaging (Nanox) is reporting stable revenue for the second quarter of the 2024 fiscal year, which ended June 30.
The company generated $2.7 million in revenue for the quarter compared with $2.6 million for the same period in 2023. It also reported a decrease in net loss between the 2023 and 2024 second quarters, posting a loss of $13.6 million this year compared with a $17.4 million loss in 2023.
Among Nanox's highlights from the quarter include submitting a 510(k) clearance submission to the U.S. Food and Drug Administration (FDA) for the Nanox.ARC for general use, including the chest, as well as receiving FDA clearance for its HealthCCSng V2.0.
Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.